Delap Wealth Advisory LLC Purchases 585 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Delap Wealth Advisory LLC grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 62.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,521 shares of the company’s stock after acquiring an additional 585 shares during the period. Delap Wealth Advisory LLC’s holdings in Medpace were worth $626,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Janney Montgomery Scott LLC increased its stake in shares of Medpace by 40.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,098 shares of the company’s stock valued at $2,175,000 after buying an additional 2,061 shares during the period. Norges Bank purchased a new stake in shares of Medpace in the 4th quarter worth about $59,163,000. PNC Financial Services Group Inc. increased its position in shares of Medpace by 5.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,750 shares of the company’s stock valued at $2,682,000 after buying an additional 488 shares during the period. Coldstream Capital Management Inc. raised its stake in Medpace by 5.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after buying an additional 45 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Medpace in the fourth quarter worth about $191,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $365.70 on Friday. The firm’s 50 day moving average price is $378.15 and its 200-day moving average price is $391.95. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The company has a market cap of $11.33 billion, a PE ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. During the same period in the prior year, the firm posted $1.93 EPS. The firm’s quarterly revenue was up 14.6% on a year-over-year basis. On average, analysts forecast that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of several research reports. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Truist Financial began coverage on shares of Medpace in a research report on Thursday, August 1st. They issued a “hold” rating and a $415.00 target price on the stock. Guggenheim dropped their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Finally, Robert W. Baird decreased their target price on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research note on Friday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and an average target price of $420.88.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.